Skip to main content

The Discrepancy Between Genetic Polymorphism of p53 Codon 72 and the Expression of p53 Protein in Helicobacter pylori-Associated Gastric Cancer in Korea

Digestive Diseases and Sciences volume 55, Article number: 101 (2010) Cite this article

Abstract

The p53 gene has been referred to as ‘the guardian of the genome’ because it controls apoptosis and cell cycle arrest. The purpose of this study was to evaluate the association of p53 codon 72 genetic polymorphism and the p53 immunohistochemistry with Helicobacter pylori-associated gastroduodenal diseases, including gastric cancer. This study included 1,852 subjects: controls and patients with gastric cancer, dysplasia, benign gastric ulcers, and duodenal ulcers (DU). Biallelic polymorphism was genotyped by restriction fragment length polymorphism. Immunohistochemical analysis for the detection of mutant type p53 expression was performed. The frequency of the Pro/Pro allele of the p53 codon 72 was higher in the patients with H. pylori-positive dysplasia than in controls (OR: 2.3, 95% CI: 1.3–4.3), but it was less frequent among patients with a H. pylori-positive DU (OR: 0.5, 95% CI: 0.3–0.8). However, there was no significant association with gastric cancer, including the location, stage, or histological type of gastric cancer. Expression of a mutant type of p53 protein was detected in 6.3% of dysplastic tissues and 26.5% of cancerous tissues compared 0% in the controls. Positive expression was higher in the intestinal type of cancer (34.9%) than in the diffuse type (15.0%; P = 0.001). These results suggest that genetic polymorphism of p53 codon 72 played a role in the determination of H. pylori-associated gastroduodenal diseases, but p53 immunostaining did not correlate with those of the p53 genetic polymorphism analysis.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Levine AJ. The p53 tumor suppressor gene and product. Cancer Surv. 1992;12:59–79.

    CAS  PubMed  Google Scholar 

  2. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323–331. doi:10.1016/S0092-8674(00)81871-1.

    Article  CAS  PubMed  Google Scholar 

  3. Shepherd T, Tolbert D, Benedetti J, et al. Alterations in exon 4 of the p53 gene in gastric carcinoma. Gastroenterology. 2000;118:1039–1044. doi:10.1016/S0016-5085(00)70356-8.

    Article  CAS  PubMed  Google Scholar 

  4. Wang YC, Lee HS, Chen SK, Chang YY, Chen CY. Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer. 1999;35:226–230. doi:10.1016/S0959-8049(98)00369-4.

    Article  CAS  PubMed  Google Scholar 

  5. Birgander R, Sjalander A, Zhou Z, Fan C, Beckman L, Beckman G. p53 polymorphisms and haplotypes in nasopharyngeal cancer. Hum Hered. 1996;46:49–54. doi:10.1159/000154325.

    Article  CAS  PubMed  Google Scholar 

  6. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis. 1993;14:1085–1089. doi:10.1093/carcin/14.6.1085.

    Article  CAS  PubMed  Google Scholar 

  7. Jin X, Wu X, Roth JA, et al. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis. 1995;16:2205–2208. doi:10.1093/carcin/16.9.2205.

    Article  CAS  PubMed  Google Scholar 

  8. Papadakis EN, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun. 2000;3:389–392. doi:10.1006/mcbr.2000.0241.

    Article  CAS  PubMed  Google Scholar 

  9. Sjalander A, Birgander R, Hallmans G, et al. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 1996;17:1313–1316. doi:10.1093/carcin/17.6.1313.

    Article  CAS  PubMed  Google Scholar 

  10. Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet. 1999;354:218–219. doi:10.1016/S0140-6736(99)01914-5.

    Article  CAS  PubMed  Google Scholar 

  11. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papilloma virus-associated cancer. Nature. 1998;393:229–234. doi:10.1038/30400.

    Article  CAS  PubMed  Google Scholar 

  12. Andersson S, Rylander E, Strand A, Sallstrom J, Wilander E. The significance of p53 codon 72 polymorphism for the development of cervical adenocarcinomas. Br J Cancer. 2001;85:1153–1156. doi:10.1054/bjoc.2001.2085.

    Article  CAS  PubMed  Google Scholar 

  13. Helland A, Langerod A, Johnsen H, Olsen AO, Skovlund E, Borresen-Dale AL. p53 polymorphism and risk of cervical cancer. Nature. 1998;396:530–531. doi:10.1038/25034.

    Article  CAS  PubMed  Google Scholar 

  14. Josefsson AM, Magnusson PK, Ylitalo N, et al. p53 polymorphism and risk of cervical cancer. Nature. 1998;396:531. doi:10.1038/25037.

    Article  CAS  PubMed  Google Scholar 

  15. Hildesheim A, Schiffman M, Brinton LA, et al. p53 polymorphism and risk of cervical cancer. Nature. 1998;396:531–532. doi:10.1038/25040.

    Article  CAS  PubMed  Google Scholar 

  16. Sonoda Y, Saigo PE, Boyd J. p53 and genetic susceptibility to cervical cancer. J Natl Cancer Inst. 1999;91:557. doi:10.1093/jnci/91.6.557.

    Article  CAS  PubMed  Google Scholar 

  17. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.

    CAS  PubMed  Google Scholar 

  18. Gonzalez CA, Sala N, Capella G. Genetic susceptibility and gastric cancer risk. Int J Cancer. 2002;100:249–260. doi:10.1002/ijc.10466.

    Article  CAS  PubMed  Google Scholar 

  19. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process. Cancer Res. 1992;52:6735–6740.

    CAS  PubMed  Google Scholar 

  20. Perez-Perez GI, Bosques-Padilla FJ, Crosatti ML, Tijerina-Menchaca R, Garza-Gonzalez E. Role of p53 codon 72 polymorphism in the risk of development of distal gastric cancer. Scand J Gastroenterol. 2005;40:56–60. doi:10.1080/00365520410009456.

    Article  CAS  PubMed  Google Scholar 

  21. Shen H, Solari A, Wang X, et al. p53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep. 2004;11:1115–1120.

    CAS  PubMed  Google Scholar 

  22. Zhang ZW, Newcomb P, Hollowood A, et al. A comparison study of gastric cancer risk in patients with duodenal and gastric ulcer: roles of gastric mucosal histology and p53 codon 72 polymorphism. Dig Dis Sci. 2004;49:254–259. doi:10.1023/B:DDAS.0000017447.02220.f5.

    Article  CAS  PubMed  Google Scholar 

  23. Xi YG, Ding KY, Su XL, et al. p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis. 2004;25:2201–2206. doi:10.1093/carcin/bgh229.

    Article  CAS  PubMed  Google Scholar 

  24. Sul J, Yu GP, Lu QY, et al. p53 codon 72 polymorphisms: a case-control study of gastric cancer and potential interactions. Cancer Lett. 2006;238:210–223. doi:10.1016/j.canlet.2005.07.004.

    Article  CAS  PubMed  Google Scholar 

  25. Hiyama T, Tanaka S, Kitadai Y, et al. p53 codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. Int J Cancer. 2002;100:304–308. doi:10.1002/ijc.10483.

    Article  CAS  PubMed  Google Scholar 

  26. Hessey SJ, Spencer J, Wyatt JI, et al. Bacterial adhesion and disease activity in Helicobacter associated chronic gastritis. Gut. 1990;31:134–138. doi:10.1136/gut.31.2.134.

    Article  CAS  PubMed  Google Scholar 

  27. Cover TL, Blaser MJ. Helicobacter pylori infection, a paradigm for chronic mucosal inflammation: pathogenesis and implications for eradication and prevention. Adv Intern Med. 1996;41:85–117.

    CAS  PubMed  Google Scholar 

  28. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev. 1997;10:720–741.

    CAS  PubMed  Google Scholar 

  29. Labigne A, de Reuse H. Determinants of Helicobacter pylori pathogenicity. Infect Agents Dis. 1996;5:191–202.

    CAS  PubMed  Google Scholar 

  30. Mobley HL. Helicobacter pylori factors associated with disease development. Gastroenterology. 1997;113(6):S21–S28.

    CAS  PubMed  Google Scholar 

  31. Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology. 1989;96(2 pt 2 Suppl):615–625.

    CAS  PubMed  Google Scholar 

  32. Lee A, Dixon MF, Danon SJ, et al. Local acid production and Helicobacter pylori: a unifying hypothesis of gastroduodenal disease. Eur J Gastroenterol Hepatol. 1995;7:461–465.

    CAS  PubMed  Google Scholar 

  33. McColl KE, el-Omar E, Gillen D. Helicobacter pylori gastritis and gastric physiology. Gastroenterol Clin North Am. 2000;29:687–703. doi:10.1016/S0889-8553(05)70138-2.

    Article  CAS  PubMed  Google Scholar 

  34. Hansson LE, Nyren O, Hsing AW, et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med. 1996;335:242–249. doi:10.1056/NEJM199607253350404.

    Article  CAS  PubMed  Google Scholar 

  35. Mastumoto Y, Marusawa H, Kinoshita K, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med. 2007;13:470–476. doi:10.1038/nm1566.

    Article  Google Scholar 

  36. Gabbert HE, Muller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer. 1995;76:720–726. doi:10.1002/1097-0142(19950901)76:5<720::AID-CNCR2820760503>3.0.CO;2-E.

    Article  CAS  PubMed  Google Scholar 

  37. Brito MJ, Williams GT, Thompson H, Filippe MI. Expression of p53 in early (T1) gastric carcinoma and precancerous adjacent mucosa. Gut. 1994;35:1697–1700. doi:10.1136/gut.35.12.1697.

    Article  CAS  PubMed  Google Scholar 

  38. Skacel M, Petras RE, Rybicki LA, et al. p53 expression in low grade dysplasia in Barrett’s esophagus: correlation with interobserver agreement and disease progression. Am J Gastroenterol. 2002;97:2508–2513. doi:10.1111/j.1572-0241.2002.06032.x.

    Article  CAS  PubMed  Google Scholar 

  39. Younes M, Erton A, Lechago LV, Somoano JR, Lechago J. p53 protein accumulation is a specific marker of malignant potential in Barrett’s metaplasia. Dig Dis Sci. 1997;42:697–701. doi:10.1023/A:1018828207371.

    Article  CAS  PubMed  Google Scholar 

  40. Weston AP, Banerjee SK, Sharma P, Tran TM, Richards R, Cherian R. p53 protein overexpression in low grade dysplasia (LGD) in Barrett’s esophagus: immunohistological marker predictive of progression. Am J Gastroenterol. 2001;96:1355–1362. doi:10.1111/j.1572-0241.2001.03851.x.

    Article  CAS  PubMed  Google Scholar 

  41. Loffeld RJ, Stobberingh E, Flendrig JA, Arends JW. Helicobacter pylori in gastric biopsy specimens. Comparison of culture, modified Giemsa stain, and immunohistochemistry. A retrospective study. J Pathol. 1991;165:69–73. doi:10.1002/path.1711650111.

    Article  CAS  PubMed  Google Scholar 

  42. Dixon MF, Genta RM, Yardley JH, Correa P. The participants on the International workshop on the Histopathology of Gastritis, Houston 1994. Classification and grading of gastritis: the Updated Sydney System. Am J Surg Pathol. 1996;20:1161–1181. doi:10.1097/00000478-199610000-00001.

    Article  CAS  PubMed  Google Scholar 

  43. Kim SY, Ahn JS, Ha YJ, et al. Serodiagnosis of Helicobacter pylori infection in Korean patients using enzyme-linked immunosorbent assay. J Immunoassay. 1998;19:251–270. doi:10.1080/01971529808005485.

    Article  CAS  PubMed  Google Scholar 

  44. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092–1100.

    CAS  PubMed  Google Scholar 

  45. Zhou Y, Li Z, Zhuang W, et al. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer. 2007;121:1481–1486. doi:10.1002/ijc.22833.

    Article  CAS  PubMed  Google Scholar 

  46. Kim JM, Lee OY, Lee CG, et al. p53 codon 72 and 16-bp duplication polymorphisms of gastric cancer in Koreans. Korean J Gastroenterol. 2007;50:292–298.

    PubMed  Google Scholar 

  47. Baker SJ, Markowitz S, Fearon ER. Suppression of human colorectal cell growth by wild-type p53. Science. 1990;249:912–915. doi:10.1126/science.2144057.

    Article  CAS  PubMed  Google Scholar 

  48. Hinds PW, Finlay CA, Quartin RS, et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the ‘hot’ spot mutant phenotypes. Cell Growth Differ. 1990;1:571–580.

    CAS  PubMed  Google Scholar 

  49. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle check point determinant following irradiation. Proc Natl Acad Sci USA. 1992;89:7491–7495. doi:10.1073/pnas.89.16.7491.

    Article  CAS  PubMed  Google Scholar 

  50. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell. 1992;70:923–935. doi:10.1016/0092-8674(92)90243-6.

    Article  CAS  PubMed  Google Scholar 

  51. Martin H, Filipe MI, Morris R, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer. 1992;50:1–4. doi:10.1002/ijc.2910500604.

    Article  Google Scholar 

  52. Joypaul BV, Newman EL, Hopwood D, et al. Expression of p53 protein in normal, dysplastic and malignant gastric mucosa: an immunohistochemical study. J Pathol. 1993;170:279–283.

    Article  CAS  PubMed  Google Scholar 

  53. Segal F, Kaspary AP, Prolla JC, Leistner S. p53 protein overexpression and p53 mutation analysis in patients with intestinal metaplasia of the cardia and Barrett’s esophagus. Cancer Lett. 2004;210:213–218. doi:10.1016/j.canlet.2004.01.020.

    Article  CAS  PubMed  Google Scholar 

  54. Hamelin R, Flejou JF, Muzeau F, et al. Tp53 gene mutations and P53 protein immunoreactivity in malignant and premalignant Barretts-esophagus. Gastroenterology. 1994;107:1012–1018.

    CAS  PubMed  Google Scholar 

  55. Coggi G, Bosari S, Roncalli M, et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma—a molecular and immunochemical study with clinicopathologic correlations. Cancer. 1997;79:425–432. doi:10.1002/(SICI)1097-0142(19970201)79:3<425::AID-CNCR1>3.0.CO;2-H.

    Article  CAS  PubMed  Google Scholar 

  56. Bian YS, Osterheld MC, Bosman FT, Benhattar J, Fontolliet C. p53 gene mutation and protein accumulation during neoplastic progression in Barrett’s esophagus. Mod Pathol. 2001;14:397–403. doi:10.1038/modpathol.3880324.

    Article  CAS  PubMed  Google Scholar 

  57. Moore JH, Lesser EJ, Erdody DH, Matale RB, Orringer MB, Beer DG. Intestinal differentiation and p53 gene alterations in Barrett's-esophagus and esophageal adenocarcinoma. Int J Cancer. 1994;56:487–493. doi:10.1002/ijc.2910560406.

    Article  CAS  PubMed  Google Scholar 

  58. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systemic review. Br J Cancer. 2005;92:434–444.

    Google Scholar 

  59. Meek DW. The p53 response to DNA damage. DNA Repair (Amst). 2004;3:1049–1056. doi:10.1016/j.dnarep2004.03.027.

    Article  CAS  Google Scholar 

  60. Murray L, Sedo A, Scott M, et al. TP53 and progression from Barrett’s metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut. 2006;55:1390–1397. doi:10.1136/gut.2005.083295.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

This work was supported by a grant from the Korean Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (no. A060266).

Author information

Affiliations

  1. Department of Internal Medicine, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam, Gyeonggi-do, 463-707, South Korea

    Nayoung Kim & Jee Hyun Kim

  2. Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea

    Nayoung Kim, Ji Hyun Park, Joo Sung Kim, Hyun Chae Jung & In Sung Song

  3. School of Public Health and Institute of Health and Environment, Seoul National University, Seoul, South Korea

    Sung-Il Cho

  4. Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, South Korea

    Hye Seung Lee

Authors
  1. Nayoung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sung-Il Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hye Seung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ji Hyun Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jee Hyun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joo Sung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hyun Chae Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. In Sung Song
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nayoung Kim.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kim, N., Cho, SI., Lee, H.S. et al. The Discrepancy Between Genetic Polymorphism of p53 Codon 72 and the Expression of p53 Protein in Helicobacter pylori-Associated Gastric Cancer in Korea. Dig Dis Sci 55, 101 (2010). https://doi.org/10.1007/s10620-008-0688-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10620-008-0688-x

Keywords

  • p53
  • Helicobacter pylori
  • Gastric cancer
  • Genetic polymorphism